Consequences of COVID-19 vaccine allocation inequity in Chicago

Sharon Zeng; Kenley M. Pelzer; Robert D. Gibbons; Monica E. Peek; William F. Parker

doi:10.1101/2021.09.22.21263984

ABSTRACT

During Chicago’s initial COVID-19 vaccine rollout, the city disproportionately allocated vaccines to zip codes with high incomes and predominantly White populations. However, the impact of this inequitable distribution on COVID-19 outcomes is unknown. This observational study determined the association between zip-code level vaccination rate and COVID-19 mortality in residents of 52 Chicago zip codes. After controlling for age distribution and recovery from infection, a 10% higher vaccination rate by March 28, 2021, was associated with a 39% lower relative risk of death during the peak of the spring wave of COVID-19. Using a difference-in-difference analysis, Chicago could have prevented an estimated 72% of deaths in the least vaccinated quartile of the city (vaccination rates of 17.8 – 26.9%) if it had had the same vaccination rate as the most vaccinated quartile (39.9 – 49.3%). Inequitable vaccine allocation in Chicago likely exacerbated existing racial disparities in COVID-19 mortality.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Support was provided by the National Institute on Aging to Sharon Zeng as part of the Pritzker Summer Research Program in Aging. William Parker was supported by the National Heart, Lung, and Blood Institute (K08 HL150291).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was a secondary analysis of publicly available, de-identified data and was granted exemption status by the University of Chicago Biological Sciences Division/University of Chicago Medical Center Institutional Review Board

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes